Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
4.23
USD
|
+1.20%
|
|
+1.20%
|
+16.21%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
266.3
|
728
|
1,098
|
1,387
|
981.3
|
1,145
|
-
|
-
|
Enterprise Value (EV)
1 |
266.3
|
728
|
1,098
|
1,387
|
679
|
897
|
872.7
|
820.7
|
P/E ratio
|
-4.78
x
|
-12
x
|
-13.7
x
|
-15.5
x
|
-91
x
|
32
x
|
18.5
x
|
11
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
4.22
x
|
11.2
x
|
14.6
x
|
13.9
x
|
4.93
x
|
4.41
x
|
3.66
x
|
3.03
x
|
EV / Revenue
|
4.22
x
|
11.2
x
|
14.6
x
|
13.9
x
|
3.41
x
|
3.45
x
|
2.79
x
|
2.17
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-81.3
x
|
4.77
x
|
6.93
x
|
4.91
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
-1.23%
|
21%
|
14.4%
|
20.3%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
206,408
|
232,601
|
251,256
|
263,196
|
269,575
|
270,763
|
-
|
-
|
Reference price
2 |
1.290
|
3.130
|
4.370
|
5.270
|
3.640
|
4.230
|
4.230
|
4.230
|
Announcement Date
|
2/25/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
63.04
|
65.14
|
75.44
|
99.77
|
199
|
259.9
|
312.8
|
377.8
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-44.6
|
-34.68
|
-47.02
|
-64.11
|
8.678
|
64.13
|
96.81
|
150
|
Operating Margin
|
-70.75%
|
-53.24%
|
-62.33%
|
-64.26%
|
4.36%
|
24.67%
|
30.95%
|
39.69%
|
Earnings before Tax (EBT)
1 |
-51.9
|
-57.46
|
-80.93
|
-87.4
|
-10.38
|
43.03
|
78.31
|
138.6
|
Net income
1 |
-51.9
|
-57.24
|
-80.93
|
-87.4
|
-11.94
|
38.84
|
73.61
|
124.7
|
Net margin
|
-82.34%
|
-87.87%
|
-107.27%
|
-87.6%
|
-6%
|
14.94%
|
23.53%
|
33.01%
|
EPS
2 |
-0.2700
|
-0.2600
|
-0.3200
|
-0.3400
|
-0.0400
|
0.1320
|
0.2283
|
0.3840
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-8.347
|
188
|
126
|
167
|
FCF margin
|
-
|
-
|
-
|
-
|
-4.2%
|
72.32%
|
40.28%
|
44.2%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
483.99%
|
171.17%
|
133.89%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/25/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
22.21
|
12.52
|
11.99
|
18.89
|
32.82
|
36.06
|
40.63
|
48.61
|
51.25
|
58.47
|
60.55
|
63.64
|
66.38
|
69.35
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-6.59
|
-23.97
|
-21.26
|
-20.45
|
-9.61
|
-12.79
|
-5.998
|
1.721
|
5.097
|
7.858
|
13.92
|
15.22
|
16.66
|
18.08
|
Operating Margin
|
-29.67%
|
-191.51%
|
-177.25%
|
-108.26%
|
-29.28%
|
-35.47%
|
-14.76%
|
3.54%
|
9.94%
|
13.44%
|
22.99%
|
23.92%
|
25.1%
|
26.07%
|
Earnings before Tax (EBT)
1 |
-4.426
|
-28.06
|
-26
|
-29.02
|
-14.43
|
-17.95
|
-9.795
|
-5.265
|
1.721
|
2.962
|
8.805
|
9.78
|
11.6
|
12.85
|
Net income
1 |
-4.426
|
-28.06
|
-26
|
-29.02
|
-14.43
|
-17.95
|
-9.795
|
-5.265
|
1.721
|
1.401
|
7.754
|
8.56
|
10.23
|
12.3
|
Net margin
|
-19.93%
|
-224.22%
|
-216.79%
|
-153.61%
|
-43.97%
|
-49.77%
|
-24.11%
|
-10.83%
|
3.36%
|
2.4%
|
12.81%
|
13.45%
|
15.41%
|
17.74%
|
EPS
2 |
-0.0200
|
-0.1100
|
-0.1000
|
-0.1100
|
-0.0600
|
-0.0700
|
-0.0400
|
-0.0200
|
0.0100
|
0.004300
|
0.0260
|
0.0300
|
0.0340
|
0.0420
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/9/21
|
2/24/22
|
5/5/22
|
8/9/22
|
11/8/22
|
2/23/23
|
5/9/23
|
8/7/23
|
11/7/23
|
2/27/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
302
|
248
|
273
|
325
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-8.35
|
188
|
126
|
167
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
2.57
|
0.8
|
11.5
|
7.59
|
42.4
|
11
|
14
|
18
|
Capex / Sales
|
4.07%
|
1.23%
|
15.2%
|
7.61%
|
21.33%
|
4.23%
|
4.48%
|
4.76%
|
Announcement Date
|
2/25/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
4.23
USD Average target price
7.083
USD Spread / Average Target +67.45% Consensus |
1st Jan change
|
Capi.
|
---|
| +16.21% | 1.15B | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|